Table 2.
Ongoing clinical studies of JAK inhibitors for COVID-19.
| Compounds | Organization | Combination | Phase/Status/Start date | NCT identifier |
|---|---|---|---|---|
| Ruxolitinib | Novartis | – | 3/Completed/November 2020 | NCT04362137 |
| Vanderson Geraldo Rocha | – | 2 & 3/Terminated/April 2021 | NCT04477993 | |
| Incyte | – | 3/Terminated/March 2021 | NCT04377620 | |
| Incyte | – | Temporarily not available/May 2021 | NCT04355793 | |
| University of Colorado | – | 2 & 3/Withdrawn/March 2021 | NCT04348071 | |
| Azienda Usl Toscana Nord Ovest | – | Not yet recruiting/April 2020 | NCT04361903 | |
| Marcelo Iastrebner | – | Phase 2/Not yet recruiting/June 2020 | NCT04414098 | |
| Fundación de investigación HM | Simvastatin | 2/Recruiting/April 2020 | NCT04348695 | |
| Washington University School of Medicine | – | 2/Withdrawn/2020 | NCT04354714 | |
| University of Jena | – | 2/Recruiting/January 2021 | NCT04338958 | |
| Grupo Cooperativo de Hemopatías Malignas | – | 1 & 2/Recruiting/February 2021 | NCT04334044 | |
| Prisma Health-Upstate | – | 2/Completed/March 2021 | NCT04374149 | |
| Philipps University Marburg Medical Center | – | 2/Active not recruited/December 2020 | NCT04359290 | |
| Assistance Publique Hopitaux De Marseille | Anakinra and Tocilizumab | 3/Not yet recruited/ June 2020 | NCT04424056 | |
| Lomonosov Moscow State University | Colchicine and Secukinumab | 2/Recruiting/May 2020 | NCT04403243 | |
| Novartis Pharmaceuticals | – | No longer available/January 2021 | NCT04337359 | |
| Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer | Anakinra | 2/Terminated/December 2020 | NCT04366232 | |
| University Health Network, Toronto | – | Not yet recruited/April 2020 | NCT04331665 | |
| Baricitinib | NIAID | Remdesivir | 3/Completed/December 2020 | NCT04280705 |
| Cambridge University Hospitals NHS Foundation Trust | Ravulizumab | 4/Recruiting/May 2020 | NCT04390464 | |
| Fabrizio Cantini | – | 2 & 3/Completed | NCT04358614 | |
| Hospital of Prato | – | 2 & 3/Not yet recruiting | NCT04320277 | |
| University of Colorado | – | 2 & 3/Withdrawn/ March 2021 | NCT04340232 | |
| University of Southern California | Hydroxychloroquine | 2/Recruiting/June 2020 | NCT04373044 | |
| Eli Lilly and Company | – | 3/Active, not recruiting/May 2021 | NCT04421027 | |
| M Abdur Rahim Medical College & Hospital | Remdesivir and Tocilizumab | 3/Recruiting/January 2021 | NCT04693026 | |
| Azienda Ospedaliero | – | 2/Not yet recruiting/May 2020 | NCT04393051 | |
| IRCCS Policlinico S. Matteo | – | 2/Not yet recruiting/May 2020 | NCT04399798 | |
| ASST Fatebenefratelli Sacco | Remdesivir and Dexamethasone | 3/Not yet recruiting/April 2021 | NCT04832880 | |
| Hospital Universitario de Fuenlabrada | Imatinib | 2/Recruiting/February 2021 | NCT04346147 | |
| ComplejoHospitalario Universitario de Albacete | – | Recruiting/April 2020 | NCT04362943 | |
| Lisa Barrett | – | 2/Recruiting/June 2020 | NCT04321993 | |
| Tofacitinib | Yale University | – | 2/Recruiting/February 2021 | NCT04415151 |
| Pfizer | – | 2/Withdrawn/February 2021 | NCT04412252 | |
| Hospital Israelita Albert Einstein | – | 2/Active, not recruiting/February 2021 | NCT04469114 | |
| I.M. Sechenov First Moscow State Medical University | – | 2/Completed/February 2021 | NCT04750317 | |
| Università Politecnica delle Marche | Hydroxychloroquine | 2/Not yet recruiting/May 2020 | NCT04390061 | |
| Università Politecnica delle Marche | – | 2/Not yet recruiting/April 2020 | NCT04332042 | |
| Pacritinib | CTI BioPharma | – | 3/Not yet recruiting/April 2021 | NCT04404361 |
Notes: ‘–‘, no combination.